Protea Biosciences — Investor Presentation (September 2017)
19 slides from Protea Biosciences's investor presentation, Sep 29, 2017
Slide 1: A Revolution In Oncology Medicine
A Revolution In Oncology Medicine
Slide 2: Molecular Information is the ultimate "big data"
2 Molecular Information is the ultimate “big data” Trillions of cells in the human body continuously produce billions of biologically - active molecules that define our health and our disease Image of a tumor within a lung Source: PhRMA 2014 Industry Profile, Alkinhibitors. com Safe Harbor Statement
Slide 3: Overview
3 Overview We develop and commercialize proprietary technology that can rapidly identify the molecules produced by living cells: Our technology is used to improve new drug development and has been adopted by pharma industry leaders. Our clients include Fortune 500 & pharma/biotech companies. We are
Slide 4: Pharma Needs Better Molecular Information
4 Pharma Needs Better Molecular Information Current state of the art does not effectively address pharma needs, e.g.: “Is my drug reaching the target” “How long does it remain biologically active?” “What other molecular changes are occurring in the target cells?” We apply our technology to offer pro
Slide 5: The Management Team
5 The Management Team Name & Title Background Stephen Turner Chairman & CEO • Founder OncorMed (Gene Logic) - cancer genomics • Founder Quorum Sciences (Sold to Vertex) • Founder Bethesda Research Laboratories (BRL - Life Technologies) David Halverson President & COO • Exec. Director, Key Accounts f
Slide 6: Advantages of Protea Technology for Oncology Diagnostics
6 Advantages of Protea Technology for Oncology Diagnostics Proteins Peptides Lipids Metabolites • Diagnosis – Accurate and objective, not subjective – Resolves ambiguous or indeterminate biopsies – Fits with current pathology routine • Management – Disease Prognosis – Treatment selection and monitor
Slide 7: Cancer Outlook and Prevalence – Clinical Need
7 Cancer Outlook and Prevalence – Clinical Need All data was taken from NIH National Cancer Institute Surveillance, Epidemiology, and End Results Program https://seer.cancer.gov/statfacts/ Cancer type Est. number of new diagnoses per year (2017) Est. number of deaths per year (2017) Percent survivin
Slide 8: Protea: Creating A New Class of Molecular Oncology Tests
8 Protea : Creating A New Class of Molecular Oncology Tests Development Partnerships with Top Tier Cancer Research Centers TEST PARTNER MARKET (USA) Malignant Melanoma Differential diagnosis Yale Medicine R. Lazova , M.D. (CA Skin Inst.) 87k new dx/year Esophageal Cancer Prognostic Breast Cancer Tre
Slide 9: Case Study: the need for an unambiguous melanoma test
9 • There are 2m biopsies per year in the US to rule out melanoma, of these, 25% or ~500k skin biopsies are labeled as indeterminate. • 41% of metastatic melanomas were missed by experts in a recent study of borderline melanocytic lesions (1) • One American dies every hour of melanoma Case Study: th
Slide 10: Protea: Molecular Oncology Test Workflow
10 Biopsy sectioned, is stained, and annotated by pathologist for specific cell regions for molecular fingerprinting Mass spectra data compared to A.I. classification algorithm Protea : Molecular Oncology Test Workflow Malignant 79 assays (98.75%) Benign 1 assay (4.76%) Data from a single sample - u
Slide 11: Molecular Diagnosis of Melanoma
11 Validation Set Number of Patients Validation Patient Accuracy Malignant Melanoma 46 94% Benign Nevi 50 92% Malignant Benign Molecular Diagnosis of Melanoma • Molecular spectra from hundreds of skin biopsies provide Big Data • Data is mined and analyzed using Artificial Intelligence and Machine Le
Slide 12: Protea: Oncology Diagnostics for Immunotherapy Management
12 Protea : Oncology Diagnostics for Immunotherapy Management “ Novel System for Immunotherapy Assessment and Prognosis in Cancer” A Collaborative Project of the Vaccine and Immunotherapy Center (VIC) Massachusetts General Hospital, Harvard Medical School and Protea Biosciences “The goal of this pro
Slide 13: Diagnostic Assays - Pipeline
13 Diagnostic Assays - Pipeline Assay Partner Launch Target Melanoma Yale 2018 Esophageal Cancer MD Anderson 2019 Breast Cancer MD Anderson 2020 Ovarian Cancer DFCI 2021 Pancreatic Cancer MD Anderson 2021 Cervical Cancer in - house 2022 Rectal Cancer MD Anderson 2022 Immunotherapy MGH 2023 3 additio
Slide 14: Diagnostic Assays - Key Development Milestones
14 Diagnostic Assays - Key Development Milestones 2017 2018 2019 2020 CLIA Lab Build - out Accreditation Melanoma Assay Sample acquisition/analysis Algorithm development Assay validation Assay launch Esophageal Cancer Assay Sample acquisition/analysis Algorithm development Assay validation Assay lau
Slide 15: Projections
15 15 Projections 2017 2018 2019 2020 2021 Total Revenue 2,088,928 11,692,875 16,729,594 33,270,492 51,699,615 Cost of Revenue 1,362,827 2,325,595 4,101,688 4,991,172 5,640,093 Gross Profit 726,101 9,367,280 12,627,906.21 28,279,319.73 46,059,521.87 Profit Margin 35% 80% 75% 85% 89% Results from Ope
Slide 16: Protea Summary Capitalization
16 Protea Summary Capitalization following 1 for 50 reverse split Summary Current Capitalization : (assumes post 1 for 50 reverse split) Common Stock ~ 8 , 034 , 499 Warrants ( 1 ) ~ 7 , 205 , 666 Options ~ 333 , 000 Convert Debt ( 2 ) ~ 2 , 163 , 358 Fully Diluted Shares Out ~ 17 , 736 , 523 (1) Ra
Slide 17: Our Industry Collaborators and Partners
17 Our Industry Collaborators and Partners Agilent Technologies (NYSE:A) – to co - develop new methods for molecular characterization of biotherapeutics ; Protein Metrics, Inc. – Software Development – to advance analytical capabilities for protein biotherapeutics MatTek Corporation – Tissue Models
Slide 18: The Harmony of Molecular Services and Molecular Diagnostics
18 The Harmony of Molecular Services and Molecular Diagnostics Molecular Services Proteomics Metabolomics Biotherapeutics Imaging Molecular Diagnostics/Prognostics Melanoma (Proteomic/Metabolomic) Esophageal (Proteomic/Metabolomic) Ovarian (Proteomic/Biotherapeutic) Wound Healing (Proteomic/Biothera
Slide 19: Investment Thesis
19 Investment Thesis Protea is uniquely positioned as a leader in the emerging industry for large scale molecular information: Proprietary technology and infrastructure is in place for enterprise success Our melanoma diagnostic workflow, will complete validation this year, is disruptive and will ena
Protea Biosciences Group — Investor Presentation (September 2017) on 6ix